FRAXEL® LASER RECEIVES
FDA CLEARANCE FOR TREATMENT OF MELASMA
On July 27, Reliant announced that the
Fraxel laser received FDA clearance to treat melasma, a stubborn
skin condition estimated to affect 6 million women worldwide. Until
now, melasma has been resistant to treatment, with traditional
laser and pulsed-light procedures considered unsatisfactory due
to lackluster results, significant downtime or the risk of adverse
complications.
“We are delighted to finally have
a successful laser treatment to offer patients who have been forced
to view the world and be viewed by the world through a mask that
could never be removed,” says dermatologist Cameron K. Rokhsar,
MD, of New York, NY, who authored a landmark paper on the topic. “With
the Fraxel laser’s unique approach of using millions of microscopic
thermal spots to gently resurface only portions of skin at a time,
we can now penetrate deep enough to eliminate the melanocytes that
cause melasma.”
“We are delighted
to finally have a successful laser treatment to offer patients
who have been forced to view the world and be viewed by the
world through a mask that could never be removed.”
— Cameron K. Rokhsar,
MD
Dr. Rokhsar's study has been submitted
to the American Society of Dermatologic Surgeons for presentation
at their annual meeting in October and was accepted by Dermatologic
Surgery with a expected publication date of December. He joined
world renowned laser pioneer Dr. Richard Fitzpatrick in the ground
breaking study: “By employing fractional resurfacing with
its distinctive wound healing response, we can not only resolve
the excessive and undesirable pigmentation at the dermal junction,
but also avoid aggravating the surrounding melanocytes, preventing
inflammatory post-treatment responses,” explains Dr. Fitzpatrick.
| Fraxel® Laser
Clinical Data on Melasma
In the Fitzpatrick/Rokhsar
study, marked to significant improvement of melasma was
achieved in 60% of 10 female subjects as assessed by
independent investigators. Effectiveness was demonstrated
by improvement in the appearance of melasma and quality
of skin texture.
|
|
Fraxel® Laser
FDA Clearances
Dermatological procedures
requiring the coagulation of soft tissue
Treatment of periorbital wrinkles
Photocoagulation of pigmented lesions including lentigos (age spots),
solar lentigos (sun spots),
and dyschromia
Melasma
Skin resurfacing procedures |
|